BACKGROUND: @entity65 after treatment is an important concern in @entity5 survivors. However, knowledge of @entity1370 is limited by the retrospective nature of data, which often does not contain details of treatment exposure. To facilitate individual risk counselling of @entity1 , we aimed to quantify the effect of @entity8253 , @entity17074 , and radiotherapy on the risk of @entity65 in @entity1 treated for @entity978 . METHODS: In 2009-10, a Life Situation Questionnaire (LSQ) was distributed to @entity1 by mail to assess late-onset effects of @entity978 treatment in @entity1 who were included in nine successive European Organisation for Research and Treatment of @entity5 (EORTC) and the Groupe d'Etude des Lymphomes de l'Adulte (GELA, now renamed LYSA) randomised trials between 1964 and 2004. We reconstructed the mean radiation doses to the heart and carotid arteries and the cumulative doses of @entity8253 and @entity17074 for all @entity1 . Incidence of @entity65 was reported during follow-up and updated through the LSQ. We applied Cox proportional hazards regression analyses to quantify the effect of chemotherapy and radiation on the risk of a first @entity65 event. FINDINGS: Information of primary treatment was complete for 6039 @entity1 (median age at diagnosis 30 years [IQR 23-40]; median length of follow-up 9 years [6-14]). 1919 @entity1 responded to the LSQ. 1238 first cardiovascular events were recorded in 703 @entity1 , most were @entity299 (132 [19%]), @entity712 (85 [12%]), @entity943 (110 [16%]), and @entity340 (77 [11%]). The mean heart radiation dose per 1 Gy increase (HR 1  015 [95% CI 1  006-1  024], p=0  0014) and the dose of @entity8253 per 50 mg/m(2) increase in cumulative dose (1  077 [1  021-1  137], p=0  0064) were significant predictors of @entity65 . Cumulative dose of @entity5713 (unadjusted model p=0  77), @entity1891 (p=0  36), and mean radiation dose to the left (p=0  41) or right (p=0  70) internal carotid artery did not predict for cardiovascular events. INTERPRETATION: Quantification of the increased cardiovascular risk with specific doses of radiation and @entity5948 exposure will enable a quantitative assessment of the optimum combination of systemic therapy and radiation, which will help clinicians to balance the risks and benefits of different regimens for individual @entity1 . FUNDING: Rigshospitalet Research Committee, the EORTC @entity5 Research Fund, and the Sally Snowman Survivorship Fellowship.

XXXX after treatment for @entity978 : an analysis of nine collaborative EORTC-LYSA trials.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity340 :: ('MESH:D006349', 'Disease') :: ['valvular disease'] @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure'] @entity8253 :: ('MESH:D018943', 'Chemical') :: ['anthracyclines'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'Cancer'] @entity17074 :: ('MESH:D014748', 'Chemical') :: ['vinca-alkaloids'] @entity5948 :: ('D018943', 'Chemical') :: ['anthracycline'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine'] @entity299 :: ('MESH:D006331', 'Disease') :: ['ischaemic heart disease'] @entity978 :: ('MESH:D006689', 'Disease') :: ["Hodgkin's lymphoma"] @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmia'] @entity1370 :: ('MESH:D066126', 'Disease') :: ['cardiotoxicity'] @entity65 :: ('MESH:D002318', 'Disease') :: ['Cardiovascular disease', 'cardiovascular disease'] @entity5713 :: ('MESH:D014747', 'Chemical') :: ['vinblastine']
@entity65 :: (MESH:D002318,Disease) :: ['Cardiovascular disease']
